Patents by Inventor Adelaida Rosa Palla

Adelaida Rosa Palla has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITION OF PROSTAGLANDIN DEGRADING ENZYME 15-PGDH TO IMPROVE JOINT STRUCTURE AND FUNCTION
    Publication number: 20240100027
    Abstract: The present disclosure provides methods of improving the structure and/or function of a joint tissue of a subject by administering to the subject an amount of a 15-PGDH inhibitor effective to inhibit 15-PGDH activity and/or reduce 15-PGDH levels in the subject. The methods described herein are useful for treating joint dysfunction and/or degeneration associated with aging, injury, disease, disorder, and/or condition.
    Type: Application
    Filed: December 9, 2021
    Publication date: March 28, 2024
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Helen M. BLAU, Nidhi BHUTANI, Mamta SINGLA, Adelaida Rosa PALLA
  • ELEVATION OF MITOCHONDRIAL BIOGENESIS AND FUNCTION BY INHIBITION OF PROSTAGLANDIN DEGRADING ENZYME 15-PGDH
    Publication number: 20240000758
    Abstract: The present disclosure provides methods of increasing mitochondrial biogenesis, function, or both in a tissue of a subject by administering to the subject an amount of a 15-PGDH inhibitor effective to inhibit 15-PGDH activity and/or reduce 15-PGDH levels in the subject. The methods described herein are useful for treating diseases, disorders, or conditions associated with dysfunctional mitochondria and/or increased oxidative stress including mitochondrial diseases.
    Type: Application
    Filed: October 22, 2021
    Publication date: January 4, 2024
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Helen M. BLAU, Adelaida Rosa PALLA, Meenakshi RAVICHANDRAN
  • REJUVENATION OF AGED TISSUES BY INHIBITION OF THE PGE2 DEGRADING ENZYME, 15-PGDH
    Publication number: 20230210829
    Abstract: The present disclosure provides compositions and methods based on the use of 15-PGDH as a therapeutic target in rejuvenation of aging non-skeletal muscle tissues and/or organs. The 15-PGDH inhibitor SW033291 administered intraperitoneally for 4 weeks resulted in restoration of follicular structure and re-establishment of the marginal zone in spleens of 25 month old mice. Treatment of 25 month old mice with SW033291 also reduced the levels of IL10, IL6, BTC, GM-CSF, IL 13 back to levels similar 0 to 4 month old mice.
    Type: Application
    Filed: June 11, 2021
    Publication date: July 6, 2023
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Helen M. Blau, Adelaida Rosa Palla, Yu Xin Wang
  • METHODS OF REJUVENATING AGED TISSUE BY INHIBITING 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE (15-PGDH)
    Publication number: 20220304992
    Abstract: The present disclosure provides compositions and methods based on the identification of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) as a therapeutic target in aging, dystrophic muscle to improve muscle atrophy, increase muscle mass, function and strength. Further provided herein are compositions and methods for the rejuvenation of aged tissue. In particular, 15-PGDH inhibitors, such as SW033291, are used to elevate the levels of prostaglandin E2 (PGE2) in the muscle or tissue.
    Type: Application
    Filed: June 11, 2020
    Publication date: September 29, 2022
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Helen M. Blau, Adelaida Rosa Palla, Andrew Tri Van Ho